Choosing cytokine and chemokine antibodies: what a tnf alpha antibody, a tnf-alpha antibody sold under the hyphenated name, an il-6 antibody, an il-1b antibody or il1 beta antibody, a cxcl9 antibody and a cxcl10 antibody each need, and why neutralising and detecting are different products
Cytokine antibodies are bought for three different jobs that a catalogue entry frequently blurs: detecting the protein, capturing it in an assay, and blocking its function in a cell experiment. Each needs different evidence, and several of these targets exist as a precursor and a processed mature form that different antibodies see differently. This page covers choosing for each job.
- the grade an antibody added to living cells requires
- carrier-free
- the FDA labelling clause behind research use only on the vial
- 809.10
- the authentication guidance a funded study is expected to follow
- NIH rigor
Figures in this panel are the validation and labelling rules a research antibody is bought and used under, named from the guidance itself and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a reagent price index it has not measured.
- 4 vendor service pages verifiedevery figure matched verbatim to the vendor's page
- Quoted and dated, never estimatedlast verification pass 2026-08-24
- 1 service classes coveredeach with measured search demand behind it
Choosing for the job
- Decide detection, capture or neutralisation first. A detection antibody binds on a blot or a section. A capture antibody works as half of a matched pair in an immunoassay. A neutralising antibody blocks a function and must show a dose response in a cell assay. These are three products and a datasheet that lists all three needs evidence for all three.
- Establish which form the antibody sees. Several of these cytokines are made as a precursor and cleaved to a mature form, and some circulate bound to soluble receptors. An antibody against the precursor region reports something different from one against the mature protein, and this explains a great deal of disagreement between published measurements.
- Use matched pairs for immunoassay, from one supplier. Capture and detection antibodies must bind different epitopes without blocking each other. Assembling a pair from two independently chosen antibodies is a development project; buying a validated pair is a purchase.
- Specify carrier-free and low endotoxin for cell work. Anything added to living cells needs a stated endotoxin limit, no azide and no bovine carrier protein. Endotoxin in a cytokine experiment is a particularly bad contaminant, because it induces the very cytokines you are measuring.
- Check species reactivity was tested, not predicted. Cytokines are less conserved than their names suggest, and cross-reactivity predicted from sequence often fails in practice. For a model organism, ask for data in that species and for neutralisation specifically, where potency differs even when binding does not.
The chemokines are a family, and cross-reactivity is real
CXCL9 and CXCL10 are induced by the same signal, share a receptor and are frequently measured together, which makes cross-reactivity between reagents an active concern rather than a theoretical one. Ask for cross-reactivity data against the closest family members.
Where both are measured, a multiplex panel validated as a set is safer than two independently chosen assays, because the supplier has had to demonstrate the pair does not interfere.
Pre-analytical handling moves the number
Several of these cytokines are released from leucocytes and platelets during clotting, so serum and plasma values differ substantially for the same donor. Fix the tube type, the time to centrifugation and the storage, and apply them to every sample.
Record the handling with the result. Most disagreements between published cytokine values come down to pre-analytical protocol rather than to the assay.
Reading a blocking experiment
Run a full dose response with an isotype control at the same concentrations, and include a positive control that blocks by another mechanism where one exists. A single concentration showing a difference is not a demonstration of neutralisation.
Check the antibody is not simply toxic at the concentration used. A viability readout alongside the functional one separates blocking from killing, and it costs one extra plate.
Common questions
- Is a tnf alpha antibody the same as a tnf-alpha antibody?
- The hyphen is a naming convention rather than a difference, and suppliers use both. What differs between products is the clone, the epitope and whether the reagent was validated for detection, capture or neutralisation.
- How do I know an antibody neutralises?
- A cell-based functional assay with a dose response and a stated half-maximal inhibitory concentration in a named system. Binding data, however strong, is not evidence of blocking and the two are frequently shown together.
- Why do two assays disagree about a cytokine concentration?
- Different antibody pairs see different forms, including precursor, mature and receptor-bound cytokine, and standards are calibrated differently. Values from two kits are generally not interchangeable.
- What grade do I need to add antibody to cells?
- Carrier-free, azide-free, sterile filtered and with a stated endotoxin limit. Endotoxin is the contaminant that matters most here because it stimulates cytokine production directly.
Get a shortlist for your project
Browse by service class
Sources
Cite or embed this figure
The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.
Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/cytokine-and-chemokine-antibodies/.